Low quality sentence examples
Ali je barem na zanimljivom mjestu što ga čini neoperabilnim.
But at least it's in a really interesting place,- which makes it totally inoperable.Dostupne kliničke informacije potječu iz objavljenih podataka o bolesnicima s neoperabilnim ili metastatskim karcinomom nadbubrežne žlijezde.
Available clinical information comes mainly from published data in patients with inoperable or metastatic adrenal carcinoma.U ovo je ispitivanje bio uključen 331 bolesnik s neoperabilnim lokalno uznapredovalim
This study included 331 patients with unresectable locally advancedPemetrexed Fresenius Kabi je u kombinaciji s cisplatinom indiciran za liječenje bolesnika s neoperabilnim malignim pleuralnim mezoteliomom koji prethodno nisu primali kemoterapiju.
Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Vemurafenib je indiciran kao monoterapija u liječenju odraslih bolesnika s neoperabilnim ili metastatskim melanomom s pozitivnom mutacijom BRAF V600 vidjeti dio 5.1.
Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma see section 5.1.placebom kontrolirano ispitivanje faze III sunitiniba kao jedinog lijeka u bolesnika s neoperabilnim pNET-om.
double-blind placebo-controlled study of single-agent sunitinib was conducted in patients with unresectable pNET.Cotellic je indiciran za primjenu u kombinaciji s vemurafenibom za liječenje odraslih bolesnika s neoperabilnim ili metastatskim melanomom s mutacijom BRAF V600 vidjeti dijelove 4.4 i 5.1.
Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation see sections 4.4 and 5.1.Docetaxel Accord u kombinaciji s cisplatinom indiciran je za liječenje bolesnika s neoperabilnim, lokalno uznapredovalim
Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advancedKadcyla je u monoterapiji indicirana za liječenje odraslih bolesnika s HER2 pozitivnim, neoperabilnim lokalno uznapredovalim
Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advancedu kombinaciji s dabrafenibom indiciran je za liječenje odraslih bolesnika s neoperabilnim ili metastatskim melanomom s pozitivnom mutacijom BRAF V600 vidjeti dijelove 4.4 i 5.1.
in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation see sections 4.4 and 5.1.placebo kontroliranom ispitivanju u bolesnika s lokalno uznapredovalim, neoperabilnim ili metastatskim rakom gušterače.
placebo-controlled trial in patients with locally advanced, unresectable or metastatic pancreatic cancer.u bolesnika s neoperabilnim pNET-om.
in patients with unresectable pNET.placebom u prvoj liniji liječenja za ispitanike s neoperabilnim( stadij IIIC)
placebo in first-line therapy for subjects with unresectable(Stage IIIC)U pasa s neoperabilnim tumorom mastocita, 2. ili 3. stupnja s izraženim mutiranim receptorom,
In dogs with non- resectable mast cell tumours,mg dvaput na dan) za liječenje odraslih bolesnika s neoperabilnim ili metastatskim melanomom s BRAF V600 mutacijom proučavale su se u dva ispitivanja faze III i jednom potpornom ispitivanju faze I/II.
in combination with dabrafenib(150 mg twice daily) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation was studied in two Phase III studies and one supportive Phase I/II study.Djelotvornost lijeka Cotellic ocjenjivala se u ispitivanju faze Ib NO25395, koje je bilo dizajnirano da ocijeni sigurnost, podnošljivost, farmakokinetiku i djelotvornost lijeka Cotellic kao dodatka vemurafenibu u liječenju bolesnika s neoperabilnim ili metastatskim melanomom pozitivnim na mutaciju BRAF V600 koja je potvrđena testom cobas® 4800 BRAF V600 Mutation Test.
The efficacy of Cotellic was evaluated in Phase Ib Study, NO25395, which was designed to assess the safety, tolerability, pharmacokinetics and efficacy of Cotellic when added to vemurafenib for the treatment of patients with BRAFV600 mutation-positive(as detected by the cobas® 4800 BRAF V600 Mutation Test), unresectable or metastatic melanoma.COIN: To je bilo otvoreno, randomizirano ispitivanje utri- skupine na 2445 bolesnika s neoperabilnim metastatskim ili lokoregionalnim kolorektalnim karcinomom koji nisu primali prethodno liječenje za metastatsku bolest a usporedilo je oksaliplatin i fluoropirimidine infuzijski 5-fluorouracil/ folna kiselina[ OxMdG] ili kapecitabin[ XELOX] u kombinaciji s cetuksimabom s istim režimom kemoterapije kao samostalnim lijekom.
COIN: This was an open-label, 3-arm, randomised study in 2445 patients with inoperable metastatic or locoregional colorectal cancer who had not received prior treatment for metastatic disease and compared oxaliplatin plus fluoropyrimidines(infusional 5-fluorouracil/folinic acid[OxMdG] or capecitabine[XELOX]) in combination with cetuximab to the same chemotherapy regimen alone.djelotvornost lijeka Cotellic u kombinaciji s vemurafenibom u odnosu na vemurafenib plus placebo u prethodno neliječenih bolesnika s neoperabilnim, lokalno uznapredovalim( stadij IIIc)
combination with vemurafenib as compared to vemurafenib plus placebo, in previously untreated patients with BRAF V600 mutation-positive unresectable locally advanced(Stage IIIc)u kojem su se ocjenjivale sigurnost i djelotvornost lijeka Cotellic u kombinaciji s vemurafenibom u odnosu na monoterapiju vemurafenibom u prethodno neliječenih bolesnika s neoperabilnim, lokalno uznapredovalim( stadij IIIc)
efficacy of Cotellic in combination with vemurafenib as compared to vemurafenib alone in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced(Stage IIIc)otvoreno kliničko ispitivanje faze III provedeno je u bolesnika s HER2-pozitivnim neoperabilnim lokalno uznapredovalim ili metastatskim rakom dojke
open-label clinical study was conducted in patients with HER2-positive unresectable locally advanced breast cancer(LABC)
